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Background
Our centers have formed an international collaborative
group composed of surgeons, pathologists, radiation
oncologists, medical oncologists and immunologists
working together with biotech and pharma sectors to
evaluate biomarkers of immune status and develop
effective combination immunotherapy for patients with
NSCLC.
Material and methods
Two phase I immunotherapies for NSCLC following surgi-
cal resection were begun at our institutions. One involved
stage I-IIIA patients given an irradiated, autologous whole-
tumour cell vaccine following induction of lymphopenia by
chemotherapy and reinfusion of autologous peripheral
blood mononuclear cells (PBMC). The other recruited
stage IV patients given an autophagosome-enriched vac-
cine generated from irradiated autologous tumour cells.
Histologic sections, enzymatically-digested tumour, pleural
effusions and apheresis are available from a number of
these patients. Current efforts are evaluating immunoscore
and immune profiling by IHC and comparing results with
flow cytometric analyses of the tumour.
Results
Preliminary studies have evaluated CD3+ CD8+
CD45RO+ cytotoxic memory T cells associated with
tumour. We are continuing to examine myeloid to
lymphoid infiltrate ratios. While preliminary, and with
only 4 patients evaluated, preexisting autologous
tumour-reactive T cells (IFN-g) were only detected
when T cells predominated in the tumour preparation
analysed. Studies comparing this with IHC staining and
analysis using Definiens software are underway.
Conclusions
A consortium of institutions has come together to
improve the outcome of patients with NSCLC. The pro-
gress made to date will be used to evaluate immune
responses to next generation immunotherapy. Evaluation
of gene expression profiling of NSCLC has identified
common overexpressed antigens and an off the shelf vac-
cine of autophagosomes containing at least 9 NCI priori-
tised cancer antigens, 5 TLR agonists and a DC targeting
molecule has been developed. A multi-center phase II
trial of combination immunotherapy for NSCLC employ-
ing this vaccine is open in the USA and efforts are under-
way to open this trial in Munich with coordinated efforts
to evaluate anti-cancer immunity in patients on this and
other trials.
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